Samenstelling van lymfklieren en het risico op afstoting na niertransplantatie.
Recruiting
- Conditions
- niertransplantatie, kidney transplantationlymfklieren, lymph nodesalemtuzumaballoreactiviteit, alloreactivityveroudering immuunsysteem, ageing of the immune systemT-folliculaire helper cellen, T-follicular helper cells
- Registration Number
- NL-OMON22565
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet the following criteria:
-Adult patients receiving a deceased or living kidney transplant in the Erasmus Medical Center Rotterdam, The Netherlands and:
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
-ABO-compatible HLA identical living-related transplant recipients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective of this study is to determine the prognostic characteristics for BPAR in the first three months after kidney transplantation, as assessed in the lymphocyte composition of the lymph node in immunologically high-risk kidney transplantation.
- Secondary Outcome Measures
Name Time Method -to capture global composition of lymph node versus blood leukocyte subsets in renal insufficiency.<br /><br>-to compare the immunological ageing profile of T cells in the peripheral blood to the T cells derived from the lymph node.<br /><br>-to assess whether pre-transplant frequencies of lymph node derived TFH, T and B cells predict BPAR.<br /><br>-to assess differences in lymphocyte composition of lymph nodes in alemtuzumab treated versus untreated patients both in single cell suspension and within the tissue. (ABO-incompatible kidney transplant recipients receive alemtuzumab induction therapy three weeks before transplantation).<br>